The positron emission tomography scan market is growing steadily as demand rises for precise diagnostic imaging across oncology, neurology, cardiology, and infectious disease care. PET scanners (including PET/CT and PET/MRI systems) provide metabolic and anatomical insights, enhancing early disease detection, treatment planning, and therapy monitoring. Growth drivers include increasing prevalence of chronic disorders like cancer and neurological conditions, technological advances (such as time-of-flight detectors, LSO crystals, and AI-enhanced imaging), and greater healthcare investments—especially in regions like North America and Asia‑Pacific. Challenges like high equipment costs, limited radiotracer access, and skilled staffing shortages remain, but ongoing innovation and policy support are expected to fuel steady market expansion globally.
According to Fortune Business Insights, the global positron emission tomography (PET) scan market was valued at USD 18.52 billion in 2024. The market is projected to grow from USD 19.31 billion in 2025 to USD 27.40 billion by 2032, exhibiting a CAGR of 5.1% during the forecast period. In 2024, North America dominated the PET scan market with a market share of 50.59%.
In June 2024, AGFA HealthCare entered a strategic partnership with Alliance Medical to introduce an advanced cloud-based imaging solution across all Alliance Medical U.K. facilities. This technology collaboration reflects growing investment in digital infrastructure for PET imaging services .